A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XmAb5871 in Patients with IgG4-Related Disease (INDIGO)
Phase of Trial: Phase III
Latest Information Update: 29 Jul 2019
Price : $35 *
At a glance
- Drugs Obexelimab (Primary)
- Indications Immunological disorders
- Focus Registrational; Therapeutic Use
- Acronyms INDIGO
- Sponsors Xencor
- 27 Jul 2019 Status changed from planning to recruiting.
- 05 Nov 2018 According to a Xencor media release, company plans to initiate this trial by Early 2019.
- 05 Oct 2018 According to a Xencor media release, this study is expected to start by year end.